Covalent polar lipid conjugates with biologically-active compoun

Details Covalent polar lipid conjugates with biologically-active compoun Covalent polar lipid conjugates with biologically-active compoun

1996-07-23

1999-10-12

Rollins, John W

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 51, 514 78, 514557, 424450, 536 268, 530300, 530329, 530331, 544243, 564153, A61K 3800, A61K 3170, A61K 31685

Patent

active

059655194

ABSTRACT:
This invention herein describes a method of facilitating the entry of drugs into cells and tissues at pharmokinetically useful levels and also a method of targeting drugs to specific organelles within the cell. This polar lipid/drug conjugate targeting invention embodies an advance over other drug targeting methods because through this method, intracellular drug concentrations may reach levels which are orders of magnitude higher than those achieved otherwise. Furthermore, it refines the drug delivery process by allowing therapeutic agents to be directed to certain intracellular structures. This technology is appropriate for use with antiproliferative, antibiotic, antimycotic, antiviral and antineoplastic drugs, in particular in combination with a multiplicity of other emollients and agents to make up topically-active substances such as salves, for rapid and efficient introduction of such agents through the epidermis for treatment of skin diseases and other disorders.

REFERENCES:
patent: 4780455 (1988-10-01), Liberman et al.
patent: 5149794 (1992-09-01), Yatvin et al.
patent: 5543389 (1996-08-01), Yatvin et al.
Abbas et al., "Antigen Presentation and T Cell Antigen Recognition," Cellular as J. Mol. Immunol. (W.B. Saunders Co.; Philadelphia), pp. 116-136.
Afzelius et al., Biochim. Biophys. Acta 979: 231-238 (1989).
Anderson et al., J. Am.Chem. Soc. 85: 3039 (1963).
Baer, Can. J. Biochem. Phys. 34: 288-304 (1955).
Barlow et al., "Mast cells and T lymphocytes in chronic urticaria," Clinical & Experimental Allergy 25: 317-322 (1995).
Berdel et al., Lipids 22: 943-946 (1987).
Boehnlein et al., "Characterization of Esterase and Alcohol Dehydrogenase Activity in Skin. Metabolism of Retinyl Palmitate to Retinol (Vitamin A) During Percutaneous Absorption," Pharmaceutical Research 11: 1155-1159 (1994).
Boman et al., "Cell-free immunity in Cecropia: A model system for antibacterial proteins," Eur. J. Biochem. 201: 23-31 (1990).
Bou-Gharios et al., "Expression of ectopeptidases in scleroderma," Annals of Rheumatic Disease 54: 111-116 (1995).
Brewster et al., "Improved Delivery through Biological Membranes XXXI: Solubilization and Stabilization of an Estradiol Chemical Delivery System by Modified .beta.-Cyclodextrins," J. Pharm. Sci. 77: 981-985 (1985).
Brown & Silvius, Biochim. Biophys. Acta 1023: 341-351 (1990).
Brown et al., "Induction of Cell Surface Peptidase Acitivity: A Global Response to Cell Stress Correlated with Apoptosis," J. Cellular Biochemistry 54: 320-331 (1994).
Buyuktimkin et al., "Synthesis and Enhancing Effect of Dodecyl 2-(N,N-Dimethylamino)propionate on the Transepidermal Delivery of Indomethacin, Clonidine, and Hydrocortisone," Pharmaceutical Research 10: 1632-1637 (1993).
Comiskey & Heath, Biochim. Biophys. Acta 1024: 307-317 (1990).
Dachun et al., "Localization and Quantification of the Nonspecific Esterase in Injured Skin for Timing of Wounds," Forensic Science International 53: 203-213 (1992).
Debs et al., Biochim. Biophys. Acta 901: 183-190 (1987).
De Magistris et al., "Antigen Analog-Major Histocompatibility Complexes Act As Antagonists of the T Cell Receptor," Cell 68: 625-634 (1992).
Dreyer et al., Proc. Natl. Acad. Sci. USA 86: 9752-9756 (1989).
Elliott et al., "Naturally processed peptides," Nature 348: 195-197 (1990).
Falk et al., "Cellular peptide composition governed by major histocompatibility complex class I molecules," Nature 348: 248-251 (1990).
Falk et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," Nature 351: 290-291 (1991).
Faustman et al., "Linkage of Faulty Major Histocompatibility Complex Class I to Autoimmune Diabetes," Science 254: 1756-1776 (1991).
Frisch et al., "Parameters affecting the immunogenicity of a liposome-associated synthetic hexapeptide antigen," Eur. J. Immun. 21: 185-193 (1991).
Germain & Hendrix, "MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding," Nature 353: 134-139 (1991).
Guery et al., "Selective Immunosuppression by Administration of Major Histocompatibility Complex (MHC) Class II-binding Peptides. I. Evidence for In Vivo MHC Blockade Preventing T Cell Activation," J. Exp. Med. 175: 1345-1352 (1992).
Hashimoto et al., Biochim. Biophys. Acta 816: 163-168 (1985).
Hashimoto et al., Biochim. Biophys. Acta 816: 169-178 (1985).
Heath and Martin, Chem. Phys. Lipids 40: 347-358 (1986).
Heath et al., Biochim.Biophys. Acta 862: 72-80 (1986).
Heath, Methods in Enzymol. 149: 111-119.
Henrikus and Kampffmeyer, "Ester hydrolysis conjugation reactions in intact skin and skin homogenate, and by liver esterase of rabbits," Xenobiotica 22: 1357-1366 (1992).
Heymann et al., "Organophosphate Sensitive and Insensitive Carboxylesterases in Human Skin," Chem. Biol. Interactions 87: 217-226 (1993).
Hopp, "Immunogenicity of a Synthetic HBsAg Peptide: Enhancement by Conjugation to a Fatty Acid Carrier," Mol. Immunol. 21: 13-16 (1984).
Hostetler et al., J. Biol. Chem. 265: 6112-6117 (1990).
Jacobson et al., FEBS Lett. 225: 97-102 (1987).
Jardetzky et al., "Identification of self peptides bound to purified HLA-B27," Nature 353: 326-329 (1991).
Kratz et al., "Keratinocyte conditioned medium stimulates type IV collagenase synthesis in cultured human keratinocytes and fibroblasts," Brit. J. Dermatology 133: 842-846 (1995).
Kinsky & Loeder, Biochim. Biophys. Acta 921: 96-103 (1987).
Kinsky et al., Biochim. Biophys. Acta 885: 129-135 (1986).
Kinsky et al., Biochim. Biophys. Acta 917: 211-218 (1987).
Kishimoto, Chem. Phys. Lipids 15: 33-36 (1975).
Koval & Pagano, J. Cell Biol. 108: 2169-2181 (1989).
Krowka et al., J. Immunol. 144: 2535-2540 (1990).
Kubota et al., "Metabolism and Degradation of Betamethasone 17-Valerate in Homogenized Living Skin Equivalent," Dermatology 188: 13-17 (1994).
Kung and Redemann, Biochim. Biophys. Acta 862: 435-439 (1986).
Lamont et al., "The use of Peptide Analogs with Improved Stability and MHC Binding Capacity to Inhibit Antigen Presentation In Vitro and In Vivo," J. Immunol. 144: 2493-2498 (1990).
Lanzavecchia et al., "Irreversible association of peptides with class II MHC molecules in living cells," Nature 357: 249-252 (1992).
Lee et al., "Antibacterial peptides from pig intestines: Isolation of a mamalian cecropin," Proc. Natl. Acad. Sci. USA 86: 9159-9162 (1989).
Lehrer et al., "Defensins: Endogenous Antibiotic Peptides of Animal Cells," Cell 64: 229-230 (1991).
Lipozencic et al., "Langerhans cells in the immunopathology of contact allergic dermatitis," Eur. J. Histochem 38: 303-310 (1994).
Loughery et al., J. Immunol. Methods 132: 25-35 (1990).
MacDonald, J. Biol. Chem. 265: 13533-13539 (1990).
Matsura et al., J. Chem. Soc. Chem. Comm. xx: 451-459 (1976).
Menger et al., "Synthesis of a Lipid/Peptide/Drug Conjugate: N4-(Acylpeptidyl)- ARA-C," Bioconjugate Chemistry 5: 162-166 (1994).
Moehrle et al., "Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histochemical study," J. Cutaneous Pathology 22: 241-247 (1995).
Mukhergee & Heidelberger, Cancer Res. 22:815-822 (1962).
Neto et al., Biochem. Biophys. Res. Commun. 171: 458-464 (1990).
Ng & Heath, Biochim. Biophys. Acta 981: 261-268 (1989).
Nothnagel, Biochim. Biophys. Acta 980: 209-219 (1989).
Pagano et al., J. Biol. Chem. 258: 2034-2040 (1983).
Parham, "Transporters of delight," Nature 348: 674-675 (1990).
Paul and Anderson, J. Am. Chem. Soc. 82: 4596-4600 (1960).
Rahman et al., Life Sci. 31: 2061-2071 (1982).
Remy et al., J. Org. Chem. 27:2491-2500 (1962).
Rosenberg et al., J. Neurochem. 48: 865-875 (1987).
Sadegh-Nasseri and Germain, "A role for peptide in determining MHC class II structure," Nature 353: 167-170 (1991).
Salord et al., Biochim. Biophys. Acta 886: 64-75 (1986).
SivaSai et al., "Effect of Recombinant Interferon Gamma Administration on Lesional Monocytes/Macrophages in Lepromatous Leprosy Patients," Int. J. Leprosy & Other Mycobacterial Diseases 61: 259-269 (1993).
Smith and Khorana, J. Amer. Chem. Soc. 80: 1141-1145 (1958).
Steim et al., Biochem. Biophys. Res. Commun. 171: 451-457 (1990).
van Wijk et al., Bioc

Affiliated with

Also associated with

Rating

Covalent polar lipid conjugates with biologically-active compoun does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Covalent polar lipid conjugates with biologically-active compoun, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Covalent polar lipid conjugates with biologically-active compoun will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-652334